Get the Stockscreener App
422.63
0.89%
-3.81
After Hours:
422.63
Vertex Pharmaceuticals Inc stock is traded at $422.63, with a volume of 1.76M.
It is down -0.89% in the last 24 hours and up +11.30% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$426.44
Open:
$427.85
24h Volume:
1.76M
Relative Volume:
0.97
Market Cap:
$108.36B
Revenue:
$11.39B
Net Income/Loss:
$3.64B
P/E Ratio:
30.21
EPS:
13.9904
Net Cash Flow:
$3.50B
1W Performance:
+3.43%
1M Performance:
+11.30%
6M Performance:
-14.17%
1Y Performance:
-10.09%
1-Day Range:
$421.26
$432.76
1-Week Range:
$406.76
$432.76
52-Week Range:
$362.50
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
422.63 | 109.29B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.00 | 62.13B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.69 | 61.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.18 | 51.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
310.03 | 34.68B | 4.56B | -176.77M | 225.30M | -1.7177 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-03-25 | Initiated | Raymond James | Mkt Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Advocacy groups form a buyer's club to obtain generic versions of pricey Vertex cystic fibrosis drug - statnews.com
Did FDA Progress on Povetacicept and New Data for ALYFTREK Just Shift Vertex’s (VRTX) Investment Narrative? - Yahoo Finance
Vertex (NASDAQ: VRTX) NACFC: - Stock Titan
Long term hold vs stop loss in Vertex Pharmaceuticals Incorporated2025 Price Action Summary & Weekly Stock Performance Updates - newser.com
Vertex price extends gainsForecast today23-10-2025 - Economies.com
How Vertex Pharmaceuticals Incorporated (VX1) stock compares with top peers2025 Top Gainers & Free Technical Pattern Based Buy Signals - newser.com
Real time pattern detection on Vertex Pharmaceuticals Incorporated stockTrade Ideas & Real-Time Chart Breakout Alerts - newser.com
Will Vertex Pharmaceuticals Incorporated bounce back from current supportPortfolio Update Summary & High Conviction Buy Zone Alerts - newser.com
Is Vertex Pharmaceuticals Incorporated stock supported by innovation pipeline2025 Bull vs Bear & Stock Portfolio Risk Control - newser.com
Promising Biotech Stocks To ResearchOctober 19th - MarketBeat
Using data tools to time your Vertex Pharmaceuticals Incorporated exitJuly 2025 Outlook & Precise Trade Entry Recommendations - newser.com
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - sharewise.com
Bank of America Securities Remains Bullish on Vertex Pharmaceuticals Incorporated (VRTX) - Insider Monkey
Vertex Pharmaceuticals (NDQ:VRTX): Another >US$100bn biotech that is facing the cliff like its peers, but might be safer - Stocks Down Under
Custom watchlist performance reports with Vertex Pharmaceuticals Incorporated2025 Fundamental Recap & AI Driven Stock Price Forecasts - newser.com
Published on: 2025-10-21 19:18:02 - newser.com
Is Vertex Pharmaceuticals Incorporated stock a safe investment in uncertain marketsTrade Exit Summary & Safe Entry Zone Identification - newser.com
Why Vertex Pharmaceuticals Incorporated (VX1) stock remains top ratedWeekly Trade Recap & Daily Profit Maximizing Tips - newser.com
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Published on: 2025-10-21 14:48:46 - newser.com
VRTX Stock Quote Price and Forecast - CNN
Vertex wins approval of new cystic fibrosis therapy Alyftrek - MSN
Published on: 2025-10-21 05:18:25 - newser.com
Momentum divergence signals in Vertex Pharmaceuticals Incorporated chart2025 Analyst Calls & Weekly Top Gainers Alerts - newser.com
How big funds are accumulating Vertex Pharmaceuticals Incorporated (VX1) stock2025 AllTime Highs & Safe Capital Growth Trade Ideas - newser.com
How Vertex Pharmaceuticals Incorporated (VX1) stock valuation compares with sector2025 Support & Resistance & Technical Pattern Recognition Alerts - nchmf.gov.vn
Is Vertex Pharmaceuticals Incorporated (VX1) stock considered safe havenRisk Management & Low Drawdown Momentum Ideas - nchmf.gov.vn
Vertex Pharmaceuticals (VRTX) Investor Outlook: Analyzing A 15% Upside Potential - DirectorsTalk Interviews
Promising Biotech Stocks To Follow TodayOctober 18th - MarketBeat
Earnings Preview: What To Expect From Vertex Pharmaceuticals' Report - MSN
Will Vertex Pharmaceuticals Incorporated stock beat EPS estimates2025 Big Picture & Daily Entry Point Trade Alerts - nchmf.gov.vn
A Closer Look at Vertex Pharmaceuticals (VRTX) Valuation After Recent Share Price Stability - Yahoo Finance
Guidance Update: Is Vertex Pharmaceuticals Incorporated stock a buy for dividend growth2025 Trading Volume Trends & AI Driven Price Predictions - nchmf.gov.vn
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know - sharewise.com
Is Vertex Pharmaceuticals Incorporated stock a buy for dividend growthBond Market & High Conviction Buy Zone Alerts - nchmf.gov.vn
Vertex IgA nephropathy asset povetacicept granted FDA rolling review - MSN
Vertex Pharmaceuticals (VRTX) Advances Povetacicept for Kidney D - GuruFocus
Goldman Sachs Cuts Vertex Pharmaceuticals Price Target to $603 From $624, Buy Rating Kept - MarketScreener
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):